ALSGD.PA down 7.72% at EURONEXT close 02 Jan 2026: key price targets

ALSGD.PA stock fell 7.72% to EUR 0.093 at the EURONEXT close on 02 Jan 2026, marking a top-loser move for the session. SpineGuard SA (ALSGD.PA) saw volume of 2,557,805.00 shares versus an average of 1,997,938.00, signalling above-average trading. We break down the drivers behind the drop, compare valuation and technicals, and set realistic near-term price targets for Europe-listed investors.

What drove the sell-off

ALSGD.PA opened at EUR 0.10 and slid to EUR 0.093 at close, a decline of 7.72% on 02 Jan 2026. The day’s high was EUR 0.10 and the low was EUR 0.093, showing a tight intraday range. Trading volume reached 2,557,805.00 shares, 1.28x the average, suggesting short-term pressure rather than a liquidity dry-up.

Trading and liquidity snapshot

Market cap stands at EUR 5,787,238.00 and shares outstanding are 62,094,833.00, placing ALSGD.PA in the microcap segment on EURONEXT. Average volume is 1,997,938.00; today’s 2,557,805.00 traded shares reflect active repositioning by traders and higher volatility relative to peers in the Healthcare sector.

Financial and valuation highlights

SpineGuard SA reports EPS of EUR -0.04 and a TTM price-to-earnings ratio of -2.33, reflecting current losses. Key valuation ratios: price-to-sales 1.45, price-to-book 1.28, and a current ratio of 1.07, indicating modest liquidity but negative operating cash flow per share of EUR -0.02.

Technical picture and sector context

Technicals are bearish: RSI at 36.61 and MACD near zero with negative momentum readings, while ATR is EUR 0.01, signalling elevated day-to-day swings. Within Healthcare on Europe markets, ALSGD.PA underperforms larger medical-device peers and the sector’s one-year trend, increasing relative downside risk for short-term traders.

Meyka AI grade and forecast

Meyka AI rates ALSGD.PA with a score out of 100: total score 66.39, grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target of EUR 0.11 and a quarterly target of EUR 0.10 versus the current price of EUR 0.093, implying a near-term upside of 18.28% to the monthly target. Forecasts are model-based projections and not guarantees.

Price targets and risks

Benchmarks to watch: year low EUR 0.08, 50-day average EUR 0.121 and 200-day average EUR 0.109 give a practical target range. Conservative short target EUR 0.08, base target EUR 0.10 and optimistic target EUR 0.12 reflect support, recent moving averages and the monthly forecast. Key risks include continued negative EPS, tight cash per share of EUR 0.01 and limited scale in the medical devices industry.

Final Thoughts

ALSGD.PA’s 7.72% drop to EUR 0.093 at the EURONEXT close on 02 Jan 2026 highlights short-term selling amid higher-than-normal volume. The company’s fundamentals show negative EPS of EUR -0.04, a PE of -2.33 and constrained cash per share of EUR 0.01, which supports caution. Technicals remain soft with RSI 36.61 and elevated short-term volatility. Our practical scenario: a conservative floor near the year low of EUR 0.08, a base recovery to EUR 0.10 and an upside case toward EUR 0.12 (near the 50-day average). Meyka AI’s forecast model projects a monthly target of EUR 0.11, implying an estimated 18.28% upside from the current EUR 0.093; forecasts are model-based projections and not guarantees. Investors should weigh small-cap liquidity, negative operating cash flows and sector competition before adding ALSGD.PA to a portfolio. For real-time updates use Meyka AI’s AI-powered market analysis platform and check the company site for product news and regulatory updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.